COCRYSTAL PHARMA INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 12
- Market Cap
- $19.2M
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Cocrystal Pharma, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06160531
- Locations
- 🇬🇧
Queen Mary BioEnterprises Innovation Centre, London, United Kingdom
CDI-988 Safety Study in Healthy Participants
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Cocrystal Pharma, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT05977140
- Locations
- 🇦🇺
Scientia Clinical Research Pty Ltd, Randwick, New South Wales, Australia
CC-42344 Safety Study in Healthy Participants
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Cocrystal Pharma, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05202379
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Cocrystal Pharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03501550
- Locations
- 🇺🇸
Institute of Human Virology University of Maryland, Baltimore, Maryland, United States
A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Cocrystal Pharma, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT02760758
- Locations
- 🇨🇦
Algorithme, Montreal, Quebec, Canada
News
Cocrystal Pharma's CC-42344 Shows 1,000-Fold Greater Potency Than Tamiflu Against H5N1 Avian Influenza
Cocrystal Pharma's investigational drug CC-42344 demonstrated exceptional antiviral activity against the highly pathogenic 2024 Texas H5N1 avian influenza strain with an EC50 of 0.003 µM.
Cocrystal Pharma's Antiviral CDI-988 Shows Potent Activity Against Emerging Norovirus Variants
Cocrystal Pharma's oral antiviral candidate CDI-988 demonstrates potent activity against emerging GII.17 norovirus variants, which have recently overtaken GII.4 as the most prevalent strain in the US and Europe.
Cocrystal Pharma Extends Phase 2a Trial of CC-42344 Influenza Inhibitor Due to Low Infection Rates
Cocrystal Pharma is extending its Phase 2a trial for CC-42344 due to unexpectedly low influenza infection rates among participants.
Cocrystal Pharma and Chemomab Therapeutics Report Progress in Antiviral and Fibro-inflammatory Drug Development
Cocrystal Pharma anticipates topline results from its Phase 2a influenza A challenge study with oral PB2 inhibitor CC-42344 by year-end.
Cocrystal Pharma's CC-42344 Shows Activity Against H5N1 Avian Influenza in Preclinical Studies
Cocrystal Pharma's broad-spectrum antiviral CC-42344 demonstrated inhibitory activity against the highly pathogenic avian influenza A (H5N1) PB2 protein in recently completed in vitro studies.